Skip to main content
SpringerLink
Log in

Quality risk assessment and DoE-based analytical quality by design approach to stability-indicating assay method for acidic degradation kinetic study of apremilast

  • Original Research Paper
  • Published:
JPC – Journal of Planar Chromatography – Modern TLC Aims and scope Submit manuscript

Abstract

Quality risk assessment and design of experiment (DoE)-based quality by design (QbD) approach has been applied for the development of a stability-indicating assay method for acidic degradation kinetic study of apremilast. Quality risk assessment started with the identification of risk factors for method development by preliminary experimentation, prior knowledge of chromatography, and brainstorming process. The identified risk factors were properly categorized and listed in fishbone diagram. Risk assessment was done by allotment of risk priority number (RPN) score to each risk factor based on preliminary experimentation. From the assessment of risk factors, the identified risk factors were checked for their main effects on resolution and tailing factors by Taguchi design. Critically identified risk factors were studied for effect on critical quality attributes by DoE-based Box–Behnken design. Method operable design region (MODR) was navigated for optimization if risk factors and control strategy were set for desired output. The separation was performed using toluene–ethyl acetate–methanol (7:1:2, v/v) on aluminum plate pre-coated with silica gel G F254. The method was validated as per the International Conference on Harmonization (ICH) Q2R1 guideline. The developed method was applied for forced degradation and acidic degradation kinetic study at different stress conditions. The degradation kinetics was found to follow the first order.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Drugbank. https://www.drugbank.ca/drugs/DB05676. Accessed: 20 April 2019

  2. Bubna AK (2016) Apremilast: a dermatologic perspective. Indian J Drugs 2:75–82. Dermatol. https://doi.org/10.4103/2455-3972.196166

    Article  Google Scholar 

  3. Gordon KB, Ruderman EM (2005) Psoriasis and psoriatic arthritis an integrated approach. Springer-Verlag, Berlin

    Book  Google Scholar 

  4. Snehalatha K, Ravindranathan R, Sriram DK, George M (2018) Utility of apremilast in the treatment of psoriasis. Int J Basic Clin Pharmacol 7(8). https://doi.org/10.18203/2319-2003.ijbcp20183013

  5. Cauli A, Porru G, Piga M, Vacca A, Dessole G, Mathieu A (2014) Clinical potential of apremilast in the treatment of psoriatic arthritis. Immunotargets Ther 3:91–96 10.2147%2FITT.S40199

    Article  Google Scholar 

  6. Prajapati PB, Partiwala C, Bodiwala KB, Marolia BP, Shah SA (2015) Alkaline degradation kinetic study of thiocolchicoside by stability indicating high performance thin layer chromatographic method. J Liq Chromatogr Relat Technol 38:1767–1782. https://doi.org/10.1080/10826076.2015.1107579

    Article  CAS  Google Scholar 

  7. Martin A, Swarbrick J, Cammarata A (2001) Physical pharmacy principles in the pharmaceutical science, 4th edn. Lippincott Williams and Wilkins, Philadelphia

    Google Scholar 

  8. Panchumarthi R, Sulthana S, Srinivasa P (2017) Development and validation of stability-indicating UV spectrophotometric method for determination of apremilast in bulk and pharmaceutical dosage form. Indian J Biotech Pharm Res 5:47–53

    Google Scholar 

  9. Lonkar NA, Dole MNS, Sawant SD (2017) Development and validation of UV-spectrophotometric method for the estimation of apremilast in bulk form by absorbance maxima method. World J Pharm PharmSci 7:758–766

    Google Scholar 

  10. Kulsum S, Sagar VG, Butul A, Fatima S, Uddin S (2016) Method development and validation of forced degradation studies of apremilast by using UV–spectrophotometric method. World J Pharm Pharm Sci 5:1595–1601. https://doi.org/10.20959/wjpps20166-6945

    Article  CAS  Google Scholar 

  11. Chakravarthy AV, Shailja BBV, Kumara P (2017) Method development and validation of ultraviolet-visible spectroscopic method for the estimation of assay of sugammadex sodium, apremilast, riociguat, and vorapaxar sulfate drugs in active pharmaceutical ingredient form. Asian J Pharm Clin Res 10(2). https://doi.org/10.22159/ajpcr.2017.v10i2.15502

  12. Panchumarthi R, Sulthana S, Kamma H (2017) Development and validation of a stability-indicating reversed phase HPLC method for determination of apremilast in bulk and pharmaceutical dosage form. Pharm Lett 9:63–73

    Google Scholar 

  13. Anerao A, Telange V, Bondre N, John S, Gathave T (2017) Stability-indicating related substances method of apremilast by HPLC and synthesis and characterization of related impurities using mass and NMR spectroscopy. Int J Curr Med Pharm Res 2:1378–1385. https://doi.org/10.4236/ajac.2017.86029

    Article  CAS  Google Scholar 

  14. Landge SB, Dahale SB, Jadhav SA, Solanki PV, Bembalkar SR, Mathad VT (2017) Development and validation of stability indicating rapid RP-LC method for determination of process and degradation related impurities of apremilast, an anti-inflammatory drug. Am J Anal Chem 8:380–394. https://doi.org/10.4236/ajac.2017.86029

    Article  CAS  Google Scholar 

  15. Lonkar NA, Sawant DS, Dole MN (2017) Development and validation of stability indicating RP-HPLC method for the estimation of apremilast by forced degradation studies. World J Pharm Pharm Sci 4:1493–1502. https://doi.org/10.20959/wjpps20174-8934

    Article  CAS  Google Scholar 

  16. Yuting L, Xiaoyue S, Taijun H, Min S (2017) Identification and characterization of process-related substances and degradation products in apremilast: process optimization and degradation pathway elucidation. J Pharm Biomed Anal 141:70–78. https://doi.org/10.1016/j.jpba.2017.03.067

    Article  CAS  Google Scholar 

  17. Chaudhri SR, Shrirkhedkar AA (2018) Application of Box–Behnken design for validation of high performance thin-layer chromatography/densitometry method for robustness determination of apremilast in bulk and in-house tablets. Pharm Methods 9:9–15. https://doi.org/10.5530/phm.2018.1.3

    Article  Google Scholar 

  18. International Conference on Harmonization (ICH) (2005) ICH harmonised tripartite guideline: validation of analytical procedures: text and methodology Q2 (R1), Geneva

  19. Anderson MJ, Whitcomb PJ (2015) DOE simplified practical tools for effective experimental, 3rd edn. CRC Press, Taylor and Frances Group, Boca Raton

    Google Scholar 

  20. International Conference on Harmonization (ICH) (2005) ICH harmonised tripartite guideline: pharmaceutical quality system Q10, Geneva

  21. Lewis GA, Mathieu D, Phan-Tan-Luu R (1998) Pharmaceutical experimental design. CRC Press, Boca Raton

    Book  Google Scholar 

Download references

Acknowledgments

The authors are thankful to Sun Pharmaceuticals, Vadodara, Gujarat, India, for providing the gift sample of apremilast and the Principal, Maliba Pharmacy College, for providing all the facilities to carry out the research work.

Author information

Authors and Affiliations

  1. Maliba Pharmacy College, Maliba Campus, Uka Tarsadia University, Bardoli, Gujarat, 394350, India

    Pintu Prajapati, Hitika Patel & Shailesh Shah

Authors
  1. Pintu Prajapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hitika Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shailesh Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pintu Prajapati.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prajapati, P., Patel, H. & Shah, S. Quality risk assessment and DoE-based analytical quality by design approach to stability-indicating assay method for acidic degradation kinetic study of apremilast. JPC-J Planar Chromat 33, 231–244 (2020). https://doi.org/10.1007/s00764-020-00036-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00764-020-00036-x

Keywords

Search

Navigation